Wegovy is semaglutide 2.4 mg given as a once-weekly injection for chronic weight management. It differs from other weight‑loss treatments in several key ways:
- How it works (mechanism)
- Wegovy is a GLP-1 receptor agonist. It helps with weight loss mainly by reducing appetite and increasing feelings of fullness, and it also slows stomach emptying.
- Other options use different mechanisms, for example:
- Orlistat blocks fat absorption in the gut.
- Phentermine/topiramate and naltrexone/bupropion work on brain pathways to suppress appetite.
- Liraglutide (Saxenda) is another GLP-1 receptor agonist but at a higher daily dose (3 mg) with a different dosing schedule.
- Dosing and how it’s taken
- Wegovy: weekly subcutaneous injections (titrated up over several weeks to 2.4 mg).
- Saxenda: daily injections of liraglutide.
- Orlistat, Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion): oral pills taken daily.
- Some newer GLP-1/GIP meds (e.g., tirzepatide) may offer different dosing patterns and potentially greater weight loss.
- What it’s approved for (indication)
- Wegovy is approved for adults with BMI ≥30, or BMI ≥27 with weight-related conditions; also approved for some adolescents (12–17) with obesity/overweight and a weight-related condition.
- Other meds have their own criteria (e.g., BMI thresholds, comorbidities) and some are approved for people without those conditions as long as specific risks are considered.
- Efficacy (how much weight loss you might expect)
- In clinical trials, Wegovy produced substantial weight loss (often roughly in the 15–20% range after about a year or more, depending on dose and study). It tends to show greater weight loss than several older non‑GLP‑1 options.
- Other medicines generally produce smaller average weight losses (often in the range of about 5–10% or a bit more, depending on the medication and individual factors). There are exceptions with newer therapies, but Wegovy’s level of weight loss is typically higher in trials.
- Cardiovascular outcomes
- Wegovy has demonstrated cardiovascular risk reduction in the SELECT trial for people with overweight/obesity and preexisting cardiovascular disease.
- Not all weight‑loss medications have proven CV risk reductions in dedicated outcomes trials.
- Safety and tolerability
- Common Wegovy side effects: nausea, diarrhea, vomiting, constipation, and stomach upset, especially at start or during dose increases.
- There are important safety considerations with GLP-1 medications (e.g., rare risks of pancreatitis, gallbladder disease; a warning about thyroid C-cell tumors in animals; contraindications for people with certain thyroid conditions or MEN2). It’s not advised in pregnancy.
- Other meds have their own safety profiles and potential adverse effects (for example, some have cardiovascular risks, mood/psychiatric effects, or risk of liver issues). Always review with a clinician.
- Practical considerations
- Administration: Wegovy requires learning how to give injections and weekly dosing; others are taken as daily pills.
- Cost and insurance coverage can vary; Wegovy often requires prior authorization and may be expensive without coverage.
- Stopping Wegovy often leads to weight regain if lifestyle changes aren’t maintained; continued therapy is usually needed for ongoing weight management.
- Other newer options
- There are other obesity treatments with different mechanisms (e.g., tirzepatide variants) that may offer different levels of weight loss and safety profiles. Availability and labeling depend on regulatory approvals and guidelines.
If you’re weighing Wegovy vs other options, it helps to discuss:
- Your BMI and weight-related health conditions
- How you’d handle injections vs pills
- Possible side effects and safety considerations
- Insurance coverage and cost
- Any other meds you take (including for diabetes, thyroid, or pregnancy plans)
I can tailor this to your situation if you share your BMI, any weight-related health issues, and whether you’re considering adult or adolescent therapy.